Bharat Biotech

Executive Summary

Bharat Biotech is a leading Indian biotechnology company specializing in the development and manufacturing of vaccines and bio-therapeutics for infectious diseases. With over two decades of experience, the company has established a strong portfolio of WHO-prequalified vaccines including those for rotavirus, typhoid, and cholera, and gained global recognition for its indigenous COVID-19 vaccine, COVAXIN. Leveraging traditional and novel vaccine platforms, Bharat Biotech focuses on addressing unmet medical needs in emerging markets. The company's commitment to innovation and public health is underscored by its state-of-the-art manufacturing facilities and a robust R&D pipeline that includes next-generation vaccines for diseases such as chikungunya, Zika, and malaria. Bharat Biotech's strategic partnerships with governments and international organizations have enabled it to scale production and expand its global footprint. The company is well-positioned to benefit from increasing vaccine demand in low- and middle-income countries. Financially, it is self-sustaining with a proven commercial track record, though it remains privately held. The company's ability to rapidly develop and deploy vaccines during the COVID-19 pandemic underscores its operational agility and technical expertise. Moving forward, Bharat Biotech is expected to continue leveraging its platforms to address emerging infectious threats and expand its product portfolio.

Upcoming Catalysts (preview)

• Q3 2027WHO prequalification of chikungunya or Zika vaccine70% success
• Q2 2027Launch of intranasal COVID-19 booster (iNCOVACC) in additional countries85% success
• H2 2028Partnership or licensing deal for next-generation malaria vaccine60% success